NASDAQ STOCKHOLM WELCOMES VICORE PHARMA TO FIRST N

Stockholm, December 10, 2015 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Vicore Pharma Holding AB’s shares (short name: VICO) commenced today on Nasdaq First North in Stockholm. Vicore Pharma belongs to the health care sector and is the 91 ^st company to be admitted to trading on Nasdaq’s Nordic markets* in 2015.

Vicore Pharma is a drug-development company specialized in research on the so called AT2 receptor, an end receptor in the Renin-Angiotensin-System, often referred to as an endogenous healing receptor when stimulated. The company's portfolio contains small molecules with potential indications including anti-inflammation, fibrotic disease, nerve generation and cardiovascular disease. Vicore Pharma’s vision is to lead the development of new molecules with agonistic action to the AT2 receptor into successful clinical drug entities. For more information, please visit www.vicorepharma.com .

“We are excited to bring Vicore Pharma and our very promising drug candidates to the stock market at the same time as we embark on a clinical program for our lead compound called C21” said Per Jansson, Managing Director of Vicore Pharma Holding. “With the support of the stock market, we believe and hope that our technology will attract the interest of both the pharma industry and investors to the benefit of our shareholders.”

“We are thrilled to welcome Vicore Pharma to our Nordic growth market, Nasdaq First North” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We continue to add exciting companies to our growing health care sector, and Vicore Pharma will make an exciting addition to this list.”

Vicore Pharma Holding AB has appointed Redeye AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market”

About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com .

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq OMX Copenhagen A/S, Nasdaq OMX Helsinki Ltd., Nasdaq OMX Iceland hf., Nasdaq OMX Riga, AS, Nasdaq OMX Stockholm AB, Nasdaq OMX Tallinn AS, AB Nasdaq OMX Vilnius, Nasdaq OMX Clearing AB, Nasdaq OMX Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.